16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment

Autores
López Torres, Manuel Othoniel; Marquina Castillo, Brenda; Ramos Espinosa, Octavio; Mata Espinosa, Dulce; Barrios Payan, Jorge A.; Baay Guzman, Guillermina; Huerta Yepez, Sara; Bini, Estela Isabel; Torre Villalvazo, Ivan; Torres, Nimbe; Tovar, Armando; Chamberlin, William; Ge, Yu; Carranza, Maria Andrea; Hernández Pando, Rogelio
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Tuberculosis (TB) is the leading cause of death from a single bacterial infectious agent and is one of the most relevant issues of public health. Another pandemic disease is type II diabetes mellitus (T2D) that is estimated to affect half a billion people in the world. T2D is directly associated with obesity and a sedentary lifestyle and is frequently associated with immunosuppression. Immune dysfunction induced by hyperglycemia increases infection frequency and severity. Thus, in developing countries the T2D/TB co-morbidity is frequent and represents one of the most significant challenges for the health-care systems. Several immunoendocrine abnormalities are occurring during the chronic phase of both diseases, such as high extra-adrenal production of active glucocorticoids (GCs) by the activity of 11-β-hydroxysteroid dehydrogenase type 1 (11-βHSD1). 11-βHSD1 catalyzes the conversion of inactive cortisone to active cortisol or corticosterone in lungs and liver, while 11-β-hydroxysteroid dehydrogenase type 2 (11-βHSD2) has the opposite effect. Active GCs have been related to insulin resistance and suppression of Th1 responses, which are deleterious factors in both T2D and TB. The anabolic adrenal hormone dehydroepiandrosterone (DHEA) exerts antagonistic effects on GC signaling in immune cells and metabolic tissues; however, its anabolic effects prohibit its use to treat immunoendocrine diseases. 16α-bromoepiandrosterone (BEA) is a water miscible synthetic sterol related to DHEA that lacks an anabolic effect while amplifying the immune and metabolic properties with important potential therapeutic uses. In this work, we compared the expression of 11-βHSD1 and the therapeutic efficacy of BEA in diabetic mice infected with tuberculosis (TB) (T2D/TB) with respect to non-diabetic TB-infected mice (TB). T2D was induced by feeding mice with a high-fat diet and administering a single low-dose of streptozotocin. After 4 weeks of T2D establishment, mice were infected intratracheally with a high-dose of Mycobacterium tuberculosis strain H37Rv. Then, mice were treated with BEA three times a week by subcutaneous and intratracheal routes. Infection with TB increased the expression of 11-βHSD1 and corticosterone in the lungs and liver of both T2D/TB and TB mice; however, T2D/TB mice developed a more severe lung disease than TB mice. In comparison with untreated animals, BEA decreased GC and 11-βHSD1 expression while increasing 11-βHSD2 expression. These molecular effects of BEA were associated with a reduction in hyperglycemia and liver steatosis, lower lung bacillary loads and pneumonia. These results uphold BEA as a promising effective therapy for the T2D/TB co-morbidity.
Fil: López Torres, Manuel Othoniel. Instituto Nacional de la Nutrición Salvador Zubiran; México
Fil: Marquina Castillo, Brenda. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Ramos Espinosa, Octavio. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Mata Espinosa, Dulce. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Barrios Payan, Jorge A.. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Baay Guzman, Guillermina. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Huerta Yepez, Sara. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Bini, Estela Isabel. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Torre Villalvazo, Ivan. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Torres, Nimbe. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Tovar, Armando. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Chamberlin, William. No especifíca;
Fil: Ge, Yu. No especifíca;
Fil: Carranza, Maria Andrea. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto Alberto C. Taquini de Investigaciones En Medicina Traslacional. - Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiologicas "prof. Dr. Alberto C. Taquini". Instituto Alberto C. Taquini de Investigaciones En Medicina Traslacional.; Argentina
Fil: Hernández Pando, Rogelio. Instituto Nacional de Ciencias Medicas y Nutricion; México
Materia
11-ΒHSD1
ACTIVE GLUCOCORTICOIDS
BEA
CENTRAL NERVOUS SYSTEM
COLONY-FORMING UNITS
DIABETES–TUBERCULOSIS CO-MORBIDITY
IMMUNOTHERAPY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/182410

id CONICETDig_8e28cfeb2f9015c3e39864db2c742a58
oai_identifier_str oai:ri.conicet.gov.ar:11336/182410
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling 16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatmentLópez Torres, Manuel OthonielMarquina Castillo, BrendaRamos Espinosa, OctavioMata Espinosa, DulceBarrios Payan, Jorge A.Baay Guzman, GuillerminaHuerta Yepez, SaraBini, Estela IsabelTorre Villalvazo, IvanTorres, NimbeTovar, ArmandoChamberlin, WilliamGe, YuCarranza, Maria AndreaHernández Pando, Rogelio11-ΒHSD1ACTIVE GLUCOCORTICOIDSBEACENTRAL NERVOUS SYSTEMCOLONY-FORMING UNITSDIABETES–TUBERCULOSIS CO-MORBIDITYIMMUNOTHERAPYhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Tuberculosis (TB) is the leading cause of death from a single bacterial infectious agent and is one of the most relevant issues of public health. Another pandemic disease is type II diabetes mellitus (T2D) that is estimated to affect half a billion people in the world. T2D is directly associated with obesity and a sedentary lifestyle and is frequently associated with immunosuppression. Immune dysfunction induced by hyperglycemia increases infection frequency and severity. Thus, in developing countries the T2D/TB co-morbidity is frequent and represents one of the most significant challenges for the health-care systems. Several immunoendocrine abnormalities are occurring during the chronic phase of both diseases, such as high extra-adrenal production of active glucocorticoids (GCs) by the activity of 11-β-hydroxysteroid dehydrogenase type 1 (11-βHSD1). 11-βHSD1 catalyzes the conversion of inactive cortisone to active cortisol or corticosterone in lungs and liver, while 11-β-hydroxysteroid dehydrogenase type 2 (11-βHSD2) has the opposite effect. Active GCs have been related to insulin resistance and suppression of Th1 responses, which are deleterious factors in both T2D and TB. The anabolic adrenal hormone dehydroepiandrosterone (DHEA) exerts antagonistic effects on GC signaling in immune cells and metabolic tissues; however, its anabolic effects prohibit its use to treat immunoendocrine diseases. 16α-bromoepiandrosterone (BEA) is a water miscible synthetic sterol related to DHEA that lacks an anabolic effect while amplifying the immune and metabolic properties with important potential therapeutic uses. In this work, we compared the expression of 11-βHSD1 and the therapeutic efficacy of BEA in diabetic mice infected with tuberculosis (TB) (T2D/TB) with respect to non-diabetic TB-infected mice (TB). T2D was induced by feeding mice with a high-fat diet and administering a single low-dose of streptozotocin. After 4 weeks of T2D establishment, mice were infected intratracheally with a high-dose of Mycobacterium tuberculosis strain H37Rv. Then, mice were treated with BEA three times a week by subcutaneous and intratracheal routes. Infection with TB increased the expression of 11-βHSD1 and corticosterone in the lungs and liver of both T2D/TB and TB mice; however, T2D/TB mice developed a more severe lung disease than TB mice. In comparison with untreated animals, BEA decreased GC and 11-βHSD1 expression while increasing 11-βHSD2 expression. These molecular effects of BEA were associated with a reduction in hyperglycemia and liver steatosis, lower lung bacillary loads and pneumonia. These results uphold BEA as a promising effective therapy for the T2D/TB co-morbidity.Fil: López Torres, Manuel Othoniel. Instituto Nacional de la Nutrición Salvador Zubiran; MéxicoFil: Marquina Castillo, Brenda. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Ramos Espinosa, Octavio. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Mata Espinosa, Dulce. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Barrios Payan, Jorge A.. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Baay Guzman, Guillermina. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Huerta Yepez, Sara. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Bini, Estela Isabel. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Torre Villalvazo, Ivan. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Torres, Nimbe. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Tovar, Armando. Instittuto de Ciencias Médicas y Nutrición; MéxicoFil: Chamberlin, William. No especifíca;Fil: Ge, Yu. No especifíca;Fil: Carranza, Maria Andrea. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto Alberto C. Taquini de Investigaciones En Medicina Traslacional. - Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiologicas "prof. Dr. Alberto C. Taquini". Instituto Alberto C. Taquini de Investigaciones En Medicina Traslacional.; ArgentinaFil: Hernández Pando, Rogelio. Instituto Nacional de Ciencias Medicas y Nutricion; MéxicoWiley Blackwell Publishing, Inc2021-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/182410López Torres, Manuel Othoniel; Marquina Castillo, Brenda; Ramos Espinosa, Octavio; Mata Espinosa, Dulce; Barrios Payan, Jorge A.; et al.; 16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment; Wiley Blackwell Publishing, Inc; Clinical and Experimental Immunology; 205; 2; 4-2021; 232-2450009-9104CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1111/cei.13603info:eu-repo/semantics/altIdentifier/doi/10.1111/cei.13603info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:34:19Zoai:ri.conicet.gov.ar:11336/182410instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:34:20.167CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv 16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment
title 16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment
spellingShingle 16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment
López Torres, Manuel Othoniel
11-ΒHSD1
ACTIVE GLUCOCORTICOIDS
BEA
CENTRAL NERVOUS SYSTEM
COLONY-FORMING UNITS
DIABETES–TUBERCULOSIS CO-MORBIDITY
IMMUNOTHERAPY
title_short 16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment
title_full 16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment
title_fullStr 16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment
title_full_unstemmed 16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment
title_sort 16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment
dc.creator.none.fl_str_mv López Torres, Manuel Othoniel
Marquina Castillo, Brenda
Ramos Espinosa, Octavio
Mata Espinosa, Dulce
Barrios Payan, Jorge A.
Baay Guzman, Guillermina
Huerta Yepez, Sara
Bini, Estela Isabel
Torre Villalvazo, Ivan
Torres, Nimbe
Tovar, Armando
Chamberlin, William
Ge, Yu
Carranza, Maria Andrea
Hernández Pando, Rogelio
author López Torres, Manuel Othoniel
author_facet López Torres, Manuel Othoniel
Marquina Castillo, Brenda
Ramos Espinosa, Octavio
Mata Espinosa, Dulce
Barrios Payan, Jorge A.
Baay Guzman, Guillermina
Huerta Yepez, Sara
Bini, Estela Isabel
Torre Villalvazo, Ivan
Torres, Nimbe
Tovar, Armando
Chamberlin, William
Ge, Yu
Carranza, Maria Andrea
Hernández Pando, Rogelio
author_role author
author2 Marquina Castillo, Brenda
Ramos Espinosa, Octavio
Mata Espinosa, Dulce
Barrios Payan, Jorge A.
Baay Guzman, Guillermina
Huerta Yepez, Sara
Bini, Estela Isabel
Torre Villalvazo, Ivan
Torres, Nimbe
Tovar, Armando
Chamberlin, William
Ge, Yu
Carranza, Maria Andrea
Hernández Pando, Rogelio
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv 11-ΒHSD1
ACTIVE GLUCOCORTICOIDS
BEA
CENTRAL NERVOUS SYSTEM
COLONY-FORMING UNITS
DIABETES–TUBERCULOSIS CO-MORBIDITY
IMMUNOTHERAPY
topic 11-ΒHSD1
ACTIVE GLUCOCORTICOIDS
BEA
CENTRAL NERVOUS SYSTEM
COLONY-FORMING UNITS
DIABETES–TUBERCULOSIS CO-MORBIDITY
IMMUNOTHERAPY
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Tuberculosis (TB) is the leading cause of death from a single bacterial infectious agent and is one of the most relevant issues of public health. Another pandemic disease is type II diabetes mellitus (T2D) that is estimated to affect half a billion people in the world. T2D is directly associated with obesity and a sedentary lifestyle and is frequently associated with immunosuppression. Immune dysfunction induced by hyperglycemia increases infection frequency and severity. Thus, in developing countries the T2D/TB co-morbidity is frequent and represents one of the most significant challenges for the health-care systems. Several immunoendocrine abnormalities are occurring during the chronic phase of both diseases, such as high extra-adrenal production of active glucocorticoids (GCs) by the activity of 11-β-hydroxysteroid dehydrogenase type 1 (11-βHSD1). 11-βHSD1 catalyzes the conversion of inactive cortisone to active cortisol or corticosterone in lungs and liver, while 11-β-hydroxysteroid dehydrogenase type 2 (11-βHSD2) has the opposite effect. Active GCs have been related to insulin resistance and suppression of Th1 responses, which are deleterious factors in both T2D and TB. The anabolic adrenal hormone dehydroepiandrosterone (DHEA) exerts antagonistic effects on GC signaling in immune cells and metabolic tissues; however, its anabolic effects prohibit its use to treat immunoendocrine diseases. 16α-bromoepiandrosterone (BEA) is a water miscible synthetic sterol related to DHEA that lacks an anabolic effect while amplifying the immune and metabolic properties with important potential therapeutic uses. In this work, we compared the expression of 11-βHSD1 and the therapeutic efficacy of BEA in diabetic mice infected with tuberculosis (TB) (T2D/TB) with respect to non-diabetic TB-infected mice (TB). T2D was induced by feeding mice with a high-fat diet and administering a single low-dose of streptozotocin. After 4 weeks of T2D establishment, mice were infected intratracheally with a high-dose of Mycobacterium tuberculosis strain H37Rv. Then, mice were treated with BEA three times a week by subcutaneous and intratracheal routes. Infection with TB increased the expression of 11-βHSD1 and corticosterone in the lungs and liver of both T2D/TB and TB mice; however, T2D/TB mice developed a more severe lung disease than TB mice. In comparison with untreated animals, BEA decreased GC and 11-βHSD1 expression while increasing 11-βHSD2 expression. These molecular effects of BEA were associated with a reduction in hyperglycemia and liver steatosis, lower lung bacillary loads and pneumonia. These results uphold BEA as a promising effective therapy for the T2D/TB co-morbidity.
Fil: López Torres, Manuel Othoniel. Instituto Nacional de la Nutrición Salvador Zubiran; México
Fil: Marquina Castillo, Brenda. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Ramos Espinosa, Octavio. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Mata Espinosa, Dulce. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Barrios Payan, Jorge A.. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Baay Guzman, Guillermina. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Huerta Yepez, Sara. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Bini, Estela Isabel. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Torre Villalvazo, Ivan. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Torres, Nimbe. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Tovar, Armando. Instittuto de Ciencias Médicas y Nutrición; México
Fil: Chamberlin, William. No especifíca;
Fil: Ge, Yu. No especifíca;
Fil: Carranza, Maria Andrea. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto Alberto C. Taquini de Investigaciones En Medicina Traslacional. - Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiologicas "prof. Dr. Alberto C. Taquini". Instituto Alberto C. Taquini de Investigaciones En Medicina Traslacional.; Argentina
Fil: Hernández Pando, Rogelio. Instituto Nacional de Ciencias Medicas y Nutricion; México
description Tuberculosis (TB) is the leading cause of death from a single bacterial infectious agent and is one of the most relevant issues of public health. Another pandemic disease is type II diabetes mellitus (T2D) that is estimated to affect half a billion people in the world. T2D is directly associated with obesity and a sedentary lifestyle and is frequently associated with immunosuppression. Immune dysfunction induced by hyperglycemia increases infection frequency and severity. Thus, in developing countries the T2D/TB co-morbidity is frequent and represents one of the most significant challenges for the health-care systems. Several immunoendocrine abnormalities are occurring during the chronic phase of both diseases, such as high extra-adrenal production of active glucocorticoids (GCs) by the activity of 11-β-hydroxysteroid dehydrogenase type 1 (11-βHSD1). 11-βHSD1 catalyzes the conversion of inactive cortisone to active cortisol or corticosterone in lungs and liver, while 11-β-hydroxysteroid dehydrogenase type 2 (11-βHSD2) has the opposite effect. Active GCs have been related to insulin resistance and suppression of Th1 responses, which are deleterious factors in both T2D and TB. The anabolic adrenal hormone dehydroepiandrosterone (DHEA) exerts antagonistic effects on GC signaling in immune cells and metabolic tissues; however, its anabolic effects prohibit its use to treat immunoendocrine diseases. 16α-bromoepiandrosterone (BEA) is a water miscible synthetic sterol related to DHEA that lacks an anabolic effect while amplifying the immune and metabolic properties with important potential therapeutic uses. In this work, we compared the expression of 11-βHSD1 and the therapeutic efficacy of BEA in diabetic mice infected with tuberculosis (TB) (T2D/TB) with respect to non-diabetic TB-infected mice (TB). T2D was induced by feeding mice with a high-fat diet and administering a single low-dose of streptozotocin. After 4 weeks of T2D establishment, mice were infected intratracheally with a high-dose of Mycobacterium tuberculosis strain H37Rv. Then, mice were treated with BEA three times a week by subcutaneous and intratracheal routes. Infection with TB increased the expression of 11-βHSD1 and corticosterone in the lungs and liver of both T2D/TB and TB mice; however, T2D/TB mice developed a more severe lung disease than TB mice. In comparison with untreated animals, BEA decreased GC and 11-βHSD1 expression while increasing 11-βHSD2 expression. These molecular effects of BEA were associated with a reduction in hyperglycemia and liver steatosis, lower lung bacillary loads and pneumonia. These results uphold BEA as a promising effective therapy for the T2D/TB co-morbidity.
publishDate 2021
dc.date.none.fl_str_mv 2021-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/182410
López Torres, Manuel Othoniel; Marquina Castillo, Brenda; Ramos Espinosa, Octavio; Mata Espinosa, Dulce; Barrios Payan, Jorge A.; et al.; 16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment; Wiley Blackwell Publishing, Inc; Clinical and Experimental Immunology; 205; 2; 4-2021; 232-245
0009-9104
CONICET Digital
CONICET
url http://hdl.handle.net/11336/182410
identifier_str_mv López Torres, Manuel Othoniel; Marquina Castillo, Brenda; Ramos Espinosa, Octavio; Mata Espinosa, Dulce; Barrios Payan, Jorge A.; et al.; 16α‐Bromoepiandrosterone as a new candidate for experimental diabetes‐tuberculosis comorbidity treatment; Wiley Blackwell Publishing, Inc; Clinical and Experimental Immunology; 205; 2; 4-2021; 232-245
0009-9104
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1111/cei.13603
info:eu-repo/semantics/altIdentifier/doi/10.1111/cei.13603
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Wiley Blackwell Publishing, Inc
publisher.none.fl_str_mv Wiley Blackwell Publishing, Inc
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613061363630080
score 13.070432